B · Normal
[Hengrui Medicine: Many of its main products will have expanded indications this year] On September 10, Hengrui Medicine stated at the 2026 semi-annual performance briefing on September 10 that many of the company's main products will have expanded indications this year: Ruikang trastuzumab for HER2-positive second-line breast cancer and dalcilib for adjuvant treatment of breast cancer, etc., have been approved in the first half of the year; in addition, the indication for chemotherapy-induced thrombocytopenia of Hetrombopag will be approved in the second half of the year.
Comments